Journal of Clinical Psychopharmacology · 1997 · 80 citations · 30 references
MedicinePharmacokineticsPharmacologyDrug MetabolismPsychopharmacologySubstance Use DisordersAddictionCytochrome P450 InteractionsDepression PharmacotherapyDrug DependenceDrug DispositionDrug-drug Interactions In MetabolismCyp1a2 Drug MetabolismCyp2d6 Drug MetabolismCyp450-mediated InteractionsCytochrome P450 2D6Cytochrome P450 Enzyme ActivitySelective Serotonin Reuptake Inhibitor TreatmentSelective Serotonin Reuptake Inhibitor UseTherapeutic Failure
Six and seven addicts treated with racemic methadone (MTD) were comedicated with fluvoxamine (FLV) and fluoxetine (FLX), respectively. The plasma concentrations of both (R)- (the active enantiomer) and (S)-MTD were increased by FLV, whereas only (R)-MTD concentrations were increased by the addition of FLX. This suggests that cytochrome P450IID6 (CYP2D6), an enzyme that is strongly inhibited by FLX, preferentially metabolizes (R)-MTD, whereas CYP1A2, which is strongly inhibited by FLV, metabolizes both enantiomers. The choice of a selective serotonin reuptake inhibitor in depressive addicted patients treated with MTD and the possible use of FLX or FLV to potentiate the effects of MTD in some cases of therapeutic failure are discussed.
30
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Kim Brøsen, Erik Skjelbo, Birgitte Buur Rasmussen et al. · Biochemical Pharmacology · 1993 · 372 citations